HUE052574T2 - Eljárás mellrákok kezelésére szelektív ösztrogén receptor modulátorral (SARM) - Google Patents

Eljárás mellrákok kezelésére szelektív ösztrogén receptor modulátorral (SARM)

Info

Publication number
HUE052574T2
HUE052574T2 HUE13817231A HUE13817231A HUE052574T2 HU E052574 T2 HUE052574 T2 HU E052574T2 HU E13817231 A HUE13817231 A HU E13817231A HU E13817231 A HUE13817231 A HU E13817231A HU E052574 T2 HUE052574 T2 HU E052574T2
Authority
HU
Hungary
Prior art keywords
sarm
breast cancer
estrogen receptor
receptor modulator
selective estrogen
Prior art date
Application number
HUE13817231A
Other languages
English (en)
Hungarian (hu)
Inventor
James Dalton
Mitchell STEINER
Ramesh Narayanan
Sunjoo Ahn
Original Assignee
Oncternal Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncternal Therapeutics Inc filed Critical Oncternal Therapeutics Inc
Publication of HUE052574T2 publication Critical patent/HUE052574T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/02—Carbamic acids; Salts of carbamic acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
HUE13817231A 2012-07-13 2013-03-07 Eljárás mellrákok kezelésére szelektív ösztrogén receptor modulátorral (SARM) HUE052574T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261671366P 2012-07-13 2012-07-13
US201261726274P 2012-11-14 2012-11-14

Publications (1)

Publication Number Publication Date
HUE052574T2 true HUE052574T2 (hu) 2021-05-28

Family

ID=49914508

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13817231A HUE052574T2 (hu) 2012-07-13 2013-03-07 Eljárás mellrákok kezelésére szelektív ösztrogén receptor modulátorral (SARM)

Country Status (20)

Country Link
US (1) US9604916B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP2872482B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (3) JP6226978B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (2) KR102238970B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (3) CN108143728A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (3) AU2013203600C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2879049C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1123542T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK2872482T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2818915T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20201463T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUE052574T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL236681B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2015DN01046A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LT2872482T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (2) MX375256B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL2872482T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT2872482T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (2) RU2648959C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2014011220A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
CA2626337C (en) 2005-10-19 2015-12-29 Chavah Pty Ltd Reduction of side effects from aromatase inhibitors used for treating breast cancer
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
IN2015DN01046A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2012-07-13 2015-06-26 Gtx Inc
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
JP5958483B2 (ja) * 2013-07-31 2016-08-02 株式会社村田製作所 電力増幅モジュール
CA2964371A1 (en) * 2014-10-16 2016-04-21 Gtx, Inc. Methods of treating urological disorders using sarms
CN113633644A (zh) 2014-10-22 2021-11-12 哈瓦赫治疗有限公司 降低乳房摄影乳腺密度和/或乳腺癌风险的方法
US10471023B2 (en) 2015-03-12 2019-11-12 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
FI3283058T3 (fi) * 2015-04-16 2023-03-01 Novartis Ag Ribosiklibitabletti
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US9834507B2 (en) 2015-04-21 2017-12-05 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
CA2983426C (en) 2015-04-21 2023-10-17 Gtx, Inc. Selective androgen receptor degrader (sard) ligands and methods of use thereof
US10035763B2 (en) 2015-04-21 2018-07-31 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
BR112017022860A2 (pt) * 2015-04-21 2018-07-17 Gtx Inc ligantes de decompostos receptores de andrógeno seletivos (sard) e métodos de utilização dos mesmos
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10017471B2 (en) 2015-04-21 2018-07-10 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
SG11201803260PA (en) 2015-10-22 2018-05-30 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
MX392461B (es) 2016-04-01 2025-03-11 Recurium Ip Holdings Llc Moduladores de receptores estrogénicos
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
AU2017278314B2 (en) * 2016-06-10 2022-06-30 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US11230523B2 (en) 2016-06-10 2022-01-25 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10806719B2 (en) 2016-06-10 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
NZ759691A (en) * 2017-06-29 2023-05-26 G1 Therapeutics Inc Morphic forms of git38 and methods of manufacture thereof
EP3793608A4 (en) 2018-05-14 2022-04-20 Nuvation Bio Inc. COMPOUNDS TARGETING ANTICANCER NUCLEAR HORMONE RECEPTORS
WO2019226991A1 (en) 2018-05-25 2019-11-28 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
WO2020051344A1 (en) 2018-09-05 2020-03-12 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
CN109761778A (zh) * 2018-12-10 2019-05-17 石家庄市度智医药科技有限公司 一种合成光学活性α-羟基丙酰胺衍生物的方法
WO2020198712A1 (en) 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
US20220202780A1 (en) * 2019-03-28 2022-06-30 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
WO2020205608A1 (en) * 2019-03-29 2020-10-08 Emory University Uses of androgen receptor antagonists and jnk pathway inhibitors, and pharmaceutical compositions related thereto
MX2021013774A (es) 2019-05-14 2021-12-10 Nuvation Bio Inc Compuestos anticancerigenos dirigidos a los receptores hormonales nucleares.
WO2020243373A1 (en) * 2019-05-29 2020-12-03 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
AU2020287392A1 (en) 2019-06-03 2021-12-23 Havah Therapeutics Pty Ltd Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use
CN114269342A (zh) 2019-08-06 2022-04-01 里科瑞尔姆Ip控股有限责任公司 用于治疗突变的雌激素受体调节剂
CA3173036A1 (en) * 2020-02-25 2021-09-02 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
US20210323931A1 (en) 2020-04-17 2021-10-21 Essa Pharma, Inc. Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof
IL297216A (en) * 2020-04-24 2022-12-01 Astrazeneca Ab Dosage regimen for cancer treatment
WO2023101710A1 (en) * 2021-12-02 2023-06-08 Veru Inc. Methods of treating breast cancers with selective androgen receptor modulators and additional therapeutic agents
WO2023172891A2 (en) * 2022-03-07 2023-09-14 Baylor College Of Medicine Biomarkers for combination therapy for er+ breast cancer
WO2023244059A1 (en) * 2022-06-15 2023-12-21 Ildong Pharmaceutical Co., Ltd. Methods of treating cancer using dual androgen receptor and pde5 inhibitor compounds
WO2024138077A1 (en) * 2022-12-21 2024-06-27 Duke University Coadministration of estrogen with estrogen receptor modulator or degrader or er targeted protac for the treatment of estrogen responsive cancers

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3256096A (en) 1961-08-11 1966-06-14 Organic Nutrients Inc Anabolic stimulator as a poultry feed supplement
US3239345A (en) 1965-02-15 1966-03-08 Estrogenic compounds and animal growth promoters
US3949085A (en) 1970-05-27 1976-04-06 Chinoin Gyogyszer-Es Vegyeszeti Termakek Gyara Rt Anabolic-weight-gain promoting compositions containing isoflavone derivatives and method using same
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
GB1360001A (en) 1971-06-16 1974-07-17 Scherico Ltd Pharmaceutical compositions comprising substituted anilides
US3875229A (en) 1972-11-24 1975-04-01 Schering Corp Substituted carboxanilides
US3865801A (en) 1973-06-15 1975-02-11 Atomic Energy Commission Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol
US3946109A (en) 1973-08-08 1976-03-23 Ernst Kolb Animal feed composition containing certain vitamin combinations
US4036979A (en) 1974-01-25 1977-07-19 American Cyanamid Company Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate
US4211781A (en) 1974-09-23 1980-07-08 Pfizer Inc. Process for the preparation of dustless quinoxaline-1,4-dioxide animal feed supplement premixes
US3991750A (en) 1975-04-28 1976-11-16 Syntex Corporation Dromostanolone propionate implant pellet useful for producing weight gains in animals and suppressing estrus in female animals
JPS6044294B2 (ja) 1976-04-15 1985-10-02 帝国臓器製薬株式会社 アニリド誘導体
US4139638A (en) 1976-09-23 1979-02-13 Schering Corporation Methods for the treatment of hirsutism
EP0002309B1 (en) 1977-10-12 1982-12-01 Imperial Chemical Industries Plc Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
US4191775A (en) 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
US4447421A (en) 1980-05-08 1984-05-08 American Cyanamid Company Process for the preparation of medicated animal feed supplement
NZ197008A (en) 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions
JPS57171904A (en) 1981-04-15 1982-10-22 Mitsubishi Petrochem Co Ltd Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide
LU88769I2 (fr) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
US4670249A (en) 1985-04-12 1987-06-02 International Minerals & Chemical Corp. Growth-promoting compositions
US4837004A (en) 1985-10-18 1989-06-06 Eastman Kodak Company Rumen-stable pellets
US4904473A (en) 1986-06-23 1990-02-27 International Minerals & Chemical Corp. Ruminant feed antacid containing potassium, sodium and chlorine
GB8617652D0 (en) 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
GB8617653D0 (en) 1986-07-18 1986-08-28 Ici Plc Amide derivatives
US4849447A (en) 1987-10-13 1989-07-18 Pitman-Moore, Inc. Zearalanol derivatives with anabolic activity
WO1989007111A1 (en) 1988-01-28 1989-08-10 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
WO1989007110A1 (en) 1988-01-28 1989-08-10 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
US4977288A (en) 1988-01-29 1990-12-11 President And Fellows Of Harvard College M-aminophenyltrialkylstannane
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5179080A (en) 1989-08-31 1993-01-12 Clinical Homecare, Corp. Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease
KR100263845B1 (ko) 1989-10-13 2000-08-16 스튜어트 엘.왓트 에리트로포이에틴 동형체와 그의 제조방법 및 그를 포함하는제약학적 조성물
US5030657A (en) 1989-10-23 1991-07-09 University Of Georgia Research Foundation, Inc. L-carnitine supplemented catfish diet
US5288496A (en) 1990-05-15 1994-02-22 Stolle Research & Development Corporation Growth promoters for animals
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
JPH09508125A (ja) 1994-01-21 1997-08-19 セプラコー，インコーポレイテッド 光学的純正ｒ−（−）−カソデックスを使用した男性ホルモン依存疾患治療のための方法と組成
US5609849A (en) 1994-03-11 1997-03-11 The Trustees Of The University Of Pennsylvania Serotonin (5-HT1A) receptor ligands and imaging agents
EP0683172B1 (en) 1994-05-19 1997-08-13 Akzo Nobel N.V. 11,21-Bisphenyl-19-norpregnane derivatives
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
WO1998005962A1 (en) 1996-08-02 1998-02-12 Panvera Corporation A method for quantitating competitive binding of molecules to proteins utilizing fluorescence polarization
US20050038110A1 (en) 2000-08-24 2005-02-17 Steiner Mitchell S. Selective androgen receptor modulators and methods of use thereof
US7205437B2 (en) 1996-11-27 2007-04-17 University Of Tennessee Research Foundation Selective androgen receptor modulators
US7759520B2 (en) 1996-11-27 2010-07-20 University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US7518013B2 (en) 2000-08-24 2009-04-14 University Of Tennessee Research Foundation Selective androgen receptor modulators
US6071957A (en) 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US6492554B2 (en) 2000-08-24 2002-12-10 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
US6995284B2 (en) 2000-08-24 2006-02-07 The University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US20090264534A1 (en) 1996-11-27 2009-10-22 Dalton James T Selective androgen receptor modulators
AU5729098A (en) 1996-12-24 1998-07-17 Zymogenetics Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US6160011A (en) 1997-05-30 2000-12-12 The University Of Tennessee Research Corporation Non-steroidal agonist compounds and their use in male hormone therapy
AU7723198A (en) 1997-06-04 1998-12-21 University Of Tennessee Research Corporation, The Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
EP0903146A1 (en) 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid
US6022137A (en) 1998-04-29 2000-02-08 Buckeye Feed Mills, Inc. Conditioner for processing raw grain composition to produce pelletized feed
DE69940063D1 (de) 1998-07-06 2009-01-22 Bristol Myers Squibb Co Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin
ATE242007T1 (de) 1998-12-23 2003-06-15 Searle Llc Kombinationen von cholesteryl ester transfer protein inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen
HRP20010688B1 (en) 1999-03-29 2008-10-31 F. Hoffmann - La Roche Ag Glucokinase activators
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
CA2388253A1 (en) 1999-10-14 2001-04-19 Bristol-Myers Squibb Company Crystallographic structure of the androgen receptor ligand binding domain
US7037919B1 (en) 1999-10-14 2006-05-02 Kaken Pharmaceutical Co. Ltd. Tetrahydroquinoline derivatives
EP1222165A2 (en) 1999-10-19 2002-07-17 Nobex Corporation Methods of asymmetrically synthesizing enantiomers of casodex, its derivatives and intermediates thereof
JP4778178B2 (ja) 1999-10-27 2011-09-21 バイオコン・リミテッド 実質的に純粋なビカルタミドの合成における中間体の分割
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
WO2001049709A1 (en) 2000-01-03 2001-07-12 Ramot University Authority For Applied Research & Industrial Development Ltd. Glycogen synthase kinase-3 inhibitors
US6441197B1 (en) 2000-01-20 2002-08-27 Daiichi Pure Chemicals Co., Ltd. Diaminofluorescein derivative
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US7713989B2 (en) 2000-04-27 2010-05-11 Dow Robert L Glucocorticoid receptor modulators
HUP0303172A3 (en) 2000-06-28 2006-05-29 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification, desing and use
US7645898B2 (en) 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US6838484B2 (en) 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
US7855229B2 (en) 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
SI1401801T1 (sl) 2000-08-24 2007-04-30 Univ Tennessee Res Foundation Selektivni modulatorji androgenskega receptorja in postopki za njihovo uporabo
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US6998500B2 (en) 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US20070173546A1 (en) 2000-08-24 2007-07-26 Dalton James T Selective androgen receptor modulators and method of use thereof
US20020173495A1 (en) 2000-08-24 2002-11-21 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US8445534B2 (en) 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US20030232792A1 (en) 2000-08-24 2003-12-18 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US7026500B2 (en) 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
US20040260108A1 (en) 2001-06-25 2004-12-23 Dalton James T. Metabolites of selective androgen receptor modulators and methods of use thereof
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US8008348B2 (en) 2001-12-06 2011-08-30 University Of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators
US20030229099A1 (en) 2000-08-30 2003-12-11 Zhu Hugh Y. Novel farnesyl protein transferase inhibitors as antitumor agents
WO2002020463A2 (en) 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
JPWO2002022585A1 (ja) 2000-09-14 2004-01-22 科研製薬株式会社 テトラヒドロキノリン化合物
SE0102300D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
DE60239207D1 (de) 2001-08-10 2011-03-31 Takeda Pharmaceutical Gnrh-agonistische kombinationsmittel
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US20060004042A1 (en) 2001-08-23 2006-01-05 Dalton James T Formulations comprising selective androgen receptor modulators
SI1666033T1 (sl) 2001-11-29 2009-06-30 Gtx Inc Preprečevanje in zdravljenje s pomankanjem androgena inducirane osteoporoze
JP4605557B2 (ja) 2001-12-06 2011-01-05 ユニバーシティ オブ テネシー リサーチ ファウンデーション 選択的アンドロゲンレセプタ修飾因子を用いた筋萎縮治療
US20070161608A1 (en) 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
AU2003207717B9 (en) 2002-02-01 2009-05-07 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
RS69704A (en) 2002-02-07 2006-12-15 Gtx Inc. Treating bening prostate hyperplasia with sarms
EA013818B1 (ru) 2002-02-28 2010-08-30 Юниверсити Оф Теннесси Рисерч Фаундейшн Полизамещённые селективные модуляторы рецептора андрогенов и способы их применения
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
US7344700B2 (en) 2002-02-28 2008-03-18 University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
US7803970B2 (en) * 2002-02-28 2010-09-28 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
BR0307981A (pt) 2002-02-28 2006-01-17 Univ Tennessee Res Foundation Compostos substituìdos de haloacetamida e azida e seus métodos de uso
JP5113979B2 (ja) 2002-02-28 2013-01-09 ユニバーシティ オブ テネシー リサーチ ファウンデーション 複数置換の選択的アンドロゲンレセプタ修飾因子及びその使用方法
BR0308355A (pt) 2002-03-13 2005-01-25 Merck & Co Inc Composto ou um sal farmaceuticamente aceitável ou um seu enanciÈmero, métodos para modular uma função mediada pelo receptor de androgênio em um mamìfero em necessidade de tal modulação, para ativar a função do receptor de androgênio em um mamìfero em necessidade de tal ativação, para tratar uma condição em um mamìfero, e para tratar osteoporose em um mamìfero em sua necessidade, composição farmacêutica, métodos para aumentar a densidade mineral óssea em um mamìfero em necessidade disto, para reduzir o risco de fraturas vertebrais ou não vertebrais em um mamìfero em necessidade disto, e para produzir um marcador de modificação óssea em um mamìfero em necessidade disto, processo para produzir uma composição farmacêutica, e, método para tratar ou prevenir uma condição artrìtica em um mamìfero em necessidade disto
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
KR20050010059A (ko) 2002-06-17 2005-01-26 유니버시티 오브 테네시 리서치 파운데이션 Ｎ-결합된 선택적 안드로겐 수용체 조절자 및 그의 사용방법
EP1398029A1 (en) 2002-09-10 2004-03-17 LION Bioscience AG NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
JP2006506369A (ja) 2002-10-15 2006-02-23 ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション メチレン架橋選択的アンドロゲン受容体調節剤及びその使用方法
JP2006505563A (ja) 2002-10-15 2006-02-16 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体調節剤による肥満治療
US20040197928A1 (en) 2002-10-15 2004-10-07 Dalton James T. Method for detecting selective androgen receptor modulators
US20040265916A1 (en) 2002-10-15 2004-12-30 Dalton James T. Method for detecting selective androgen receptor modulators
EP1562906A4 (en) 2002-10-15 2009-12-02 Univ Tennessee Res Foundation HETEROCYCLIC SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHOD FOR THEIR USE
US20040087810A1 (en) 2002-10-23 2004-05-06 Dalton James T. Irreversible selective androgen receptor modulators and methods of use thereof
US20140011774A1 (en) 2002-12-05 2014-01-09 University Of Tennessee Research Foundation Selective androgen receptor modulators
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
WO2004060146A2 (en) 2002-12-30 2004-07-22 Purdue Research Foundation Method of treatment for central nervous system injury
ES2420129T3 (es) 2003-01-13 2013-08-22 University Of Tennessee Research Foundation Síntesis en gran escala de moduladores selectivos del receptor de andrógenos
AU2004207492A1 (en) * 2003-01-22 2004-08-12 Gtx Inc. A method of treating breast cancer with androgen receptor antagonists
WO2004064747A2 (en) * 2003-01-22 2004-08-05 Gtx Inc. Treating androgen deficiency in female (adif)-associated conditions with sarms
US20040167103A1 (en) * 2003-02-24 2004-08-26 Dalton James T. Haloacetamide and azide substituted compounds and methods of use thereof
GB0308335D0 (en) 2003-04-10 2003-05-14 Novartis Ag Organic compounds
CN1325506C (zh) 2003-05-15 2007-07-11 中国科学院上海药物研究所 骨重吸收抑制剂阿伦膦酸及生理可接受的盐和它的制备
US20060165744A1 (en) 2003-05-22 2006-07-27 Neopharm, Inc Combination liposomal formulations
FI20030958A0 (fi) 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
AU2004272004B2 (en) 2003-09-10 2009-01-22 Merck Sharp & Dohme Corp. 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
AU2004271740B2 (en) 2003-09-12 2010-10-28 Merck Serono Sa Benzothiazole derivatives for the treatment of diabetes
EP2476415A3 (en) 2003-10-14 2012-08-29 University of Tennessee Research Foundation Treating bone-related disorders with selective androgen receptor modulators
US20050137172A1 (en) * 2003-10-15 2005-06-23 Dalton James T. Haloacetamide and azide substituted compounds and methods of use thereof
TW200523235A (en) 2003-10-15 2005-07-16 Gtx Inc Anti-cancer compounds and methods of use thereof
GB0325402D0 (en) 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
CA2522874A1 (en) 2003-12-16 2005-07-07 Gtx, Inc. Prodrugs of selective androgen receptor modulators and methods of use thereof
TW200530181A (en) 2004-01-13 2005-09-16 Bristol Myers Squibb Co Heterocyclic compounds useful as growth hormone secretagogues
ATE439357T1 (de) 2004-05-03 2009-08-15 Hoffmann La Roche Indolylderivate als liver-x-rezeptormodulatoren
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US20130034562A1 (en) 2004-06-07 2013-02-07 Dalton James T Selective androgen receptor modulators for treating diabetes
WO2005120483A2 (en) 2004-06-07 2005-12-22 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
BRPI0513367A (pt) 2004-07-14 2008-05-06 Janssen Pharmaceutica Nv arilidenos para o tratamento de doenças mediadas pelo receptor alfa relacionado a estrogênio
US7825229B2 (en) 2005-03-25 2010-11-02 Rosetta Genomics Ltd. Lung cancer-related nucleic acids
AU2006285026B2 (en) 2005-08-31 2012-08-09 University Of Tennessee Research Foundation Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators
JP2009513704A (ja) 2005-11-01 2009-04-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ グルコキナーゼのアロステリックモジュレーターとしての置換ジヒドロイソインドロン
US7531671B2 (en) 2005-11-01 2009-05-12 Janssen Pharmaceutica N.V. Dihydroisoindolones as allosteric modulators of glucokinase
US8158828B2 (en) 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
US20070135407A1 (en) 2005-11-28 2007-06-14 Steiner Mitchell S Serm reduction of lipid profiles
EP1962835A2 (en) 2005-12-21 2008-09-03 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or h3 receptor antagonist/inverse agonist
EP1801140A1 (en) 2005-12-22 2007-06-27 Mnemoscience GmbH Macro-diacrylate
US8168216B2 (en) * 2006-03-22 2012-05-01 Medigene Ag Treatment of triple receptor negative breast cancer
ES2780193T3 (es) 2006-07-12 2020-08-24 Univ Tennessee Res Found Compuesto para tratar el cáncer de mama y afecciones dependientes de la progestina
MX2009001962A (es) 2006-08-24 2009-04-30 Univ Tennessee Res Foundation Acilanilidas substituidas y metodos de uso de las mismas.
CA2676066C (en) 2007-01-22 2016-06-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
MX336760B (es) 2007-09-11 2016-01-29 Univ Tennessee Res Foundation Formas solidas de moduladores selectivos de receptor de androgenos.
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US8003689B2 (en) 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
ES2546410T3 (es) * 2009-08-06 2015-09-23 John Wayne Cancer Institute Diagnosis de cáncer de mama, y otros tipos de cáncer, de tipo basal primario y metastásico
BR112012009262A2 (pt) * 2009-10-23 2019-09-24 Health Research Inc ''método para inibir a proliferação de células de câncer positivo para ar em um indivíduo diagnosticado com,ou qual se suspeita que tenha cânce positivo para ar e método para identificar se um indivíduo é um candidato para tratamento com uma composiçâo
EP2523556A4 (en) 2010-01-11 2013-08-28 Gtx Inc METHOD FOR TREATING MIBROMED DYNAMIC FUNCTION
UY33740A (es) * 2010-11-18 2012-05-31 Takeda Pharmaceutical Método para tratar el cáncer de mama y cáncer de ovarios
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
IN2015DN01046A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2012-07-13 2015-06-26 Gtx Inc

Also Published As

Publication number Publication date
ES2818915T3 (es) 2021-04-14
AU2018201450B2 (en) 2019-06-13
PT2872482T (pt) 2020-09-22
RU2017141776A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2019-02-13
WO2014011220A3 (en) 2015-03-05
RU2648959C2 (ru) 2018-03-28
KR102238970B1 (ko) 2021-04-09
JP2015522069A (ja) 2015-08-03
RU2017141776A (ru) 2019-02-13
US20140018433A1 (en) 2014-01-16
LT2872482T (lt) 2020-12-28
JP2017101088A (ja) 2017-06-08
DK2872482T3 (da) 2020-09-21
MX2020009725A (es) 2020-10-08
EP2872482A2 (en) 2015-05-20
EP3733170A1 (en) 2020-11-04
IN2015DN01046A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-06-26
AU2013203600A1 (en) 2014-01-30
AU2013203600B2 (en) 2016-03-03
MX375256B (es) 2025-03-06
KR20150038085A (ko) 2015-04-08
EP2872482A4 (en) 2016-03-30
PL2872482T3 (pl) 2021-03-08
US9604916B2 (en) 2017-03-28
IL236681B (en) 2021-04-29
IL236681A0 (en) 2015-02-26
AU2016203696B2 (en) 2017-11-30
AU2018201450A1 (en) 2018-03-22
JP2018168201A (ja) 2018-11-01
KR102122941B1 (ko) 2020-06-15
AU2013203600C1 (en) 2016-11-24
RU2717835C2 (ru) 2020-03-26
JP6386120B2 (ja) 2018-09-05
JP6759290B2 (ja) 2020-09-23
AU2016203696A1 (en) 2016-06-23
HRP20201463T1 (hr) 2021-04-02
CA2879049A1 (en) 2014-01-16
WO2014011220A2 (en) 2014-01-16
EP2872482B1 (en) 2020-07-08
CA2879049C (en) 2021-02-23
MX2015000572A (es) 2015-09-23
CN108143728A (zh) 2018-06-12
KR20200069394A (ko) 2020-06-16
RU2015104780A (ru) 2016-08-27
CN110840870A (zh) 2020-02-28
CN104754939A (zh) 2015-07-01
JP6226978B2 (ja) 2017-11-08
CY1123542T1 (el) 2022-03-24

Similar Documents

Publication Publication Date Title
HUE052574T2 (hu) Eljárás mellrákok kezelésére szelektív ösztrogén receptor modulátorral (SARM)
CY2024004I2 (el) Θεραπεια καρκινου μαστου χρησιμοποιωντας εκλεκτικους ρυθμιστες υποδοχεα οιστρογονου
IL237791B (en) Method of treating cancer
IL235355B (en) Methid for generating t cell receptors
EP2915057A4 (en) METHOD FOR CONFIGURING A COMMUNICATION DEVICE THROUGH A CONFIGURATION FILE LOCATION
ZA201600117B (en) Apparatus for endothermic reactions
BR112014008232A2 (pt) aparelhos de recepção e transmissão, e, métodos para recepção de um aparelho de recepção e para transmissão de um aparelho de transmissão
BR112015003847A2 (pt) dispositivo flexível, e método para operar um dispositivo flexível
IL237436A0 (en) A method for screening cancer
PT2876447T (pt) Método para deteção de cancro
EP2800476A4 (en) Method of feeding
DE112013000135A5 (de) Vorrichtung zum Bereitstellen elektromagnetischer Strahlung
GB201306544D0 (en) Method for releasing overlaps
HUE043162T2 (hu) Eljárás rák detektálására
DK3608421T3 (da) Fremgangsmåde til screening for colorektal cancer
GB201201379D0 (en) Method and apparatus for configuring a resource allaocation
IL231440A0 (en) Selective androgen receptor modulators
IL254964A0 (en) A method for treating breast cancer
RS58500B1 (sr) Uređaj za orijentisanje mašina za bušenje
EP2803738A4 (en) METHOD FOR OPERATING A FLASHING BALLOON
HUE046344T2 (hu) Új ösztrogén receptor ligandumok
GB201314104D0 (en) Apparatus for making a laboratory sample carrier
BR112015001280A2 (pt) conjunto de fixação, método para fixar um conjunto de fixação e método de fixação de um dispositivo
ES1077883Y (es) Dispositivo percutor hidraulico para maquinas excavadoras
ITMI20131369A1 (it) Apparato per disporre calze.